Delisting risk
Cuprina Class A (CUPR)
Develops prescription live-larva products for chronic-wound debridement.
$2.75
Pre-market−0.09 (−3.17%)
At close$2.84(−2.07%)
Something off on this page? Send us feedback.
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Jul 2026 | — | — | — |
| May 2026 | — | — | — |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | — | — | — | — | — | — | — |
| May 13, 2026 | — | — | — | — | — | — | — |